Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05010811
Other study ID # 2016-122
Secondary ID
Status Completed
Phase
First received
Last updated
Start date October 22, 2016
Est. completion date April 28, 2017

Study information

Verified date September 2016
Source Second Affiliated Hospital, School of Medicine, Zhejiang University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Isolation lung cysticercosis reports are rare in literature. Most lung lesions were characterized by nodules. The investigators access one case which was characterized with pulmonary cavity and pleural effusion by Gupta N, et al in 2015 from PUBMED and Medline. But pleural effusion and exudative lesions is reported for the first time.


Description:

Cysticercosis is an important public health problem in developing countries. The major involvement sites are the central nervous system and the eyes,although striated muscles and subcutaneous tissues are frequently involved in the disseminated form of disease. Pulmonary involvement in cysticercosis is very rare and ill-defined nodular shadows distributed throughout the lung is the usual radiological presentation. Only one case of cysticercosis presenting as lung cavity with pleural effusion has been reported so far in literature. The investigators describe two cases in which pleural effusion due to cysticercosis were detected on X and CT.


Recruitment information / eligibility

Status Completed
Enrollment 2
Est. completion date April 28, 2017
Est. primary completion date January 18, 2017
Accepts healthy volunteers No
Gender All
Age group 45 Years to 67 Years
Eligibility Inclusion Criteria: 1. Clinical diagnosis of Pulmonary Cysticercosis? 2. With pleural effusion Exclusion Criteria: 1.No cysticercosis was found by biopsy or antibody test

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Second Affiliated Hospital, School of Medicine, Zhejiang University

Outcome

Type Measure Description Time frame Safety issue
Primary Amount of pleural effusion cm 9 months
Primary Rate of Eosinophil ratio Percentage(%) 9 months
Primary Changes of lesions under chest radiography or CT no change, change, complete absorption 9 months
See also
  Status Clinical Trial Phase
Recruiting NCT00001205 - Natural History of Treated Neurocysticercosis and Long-Term Outcomes
Completed NCT00004403 - Randomized Study of Albendazole in Patients With Epilepsy Due to Neurocysticercosis N/A
Completed NCT03095339 - EFECAB: Improving Pig Management to Prevent Epilepsy in Burkina Faso N/A
Completed NCT00001912 - Brain Tissue Swelling and Seizure Activity in Inactive Cysticercosis N/A
Completed NCT01368354 - Taenia Solium Control Case Study in Zambia N/A
Completed NCT03808597 - Digital Health Promotion in Iringa, Tanzania N/A